Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts

Kyoung-Min Choi,Boram Kim,Su-Min Lee,Jisoo Han,Ha-Song Bae,Su-Bhin Han,Dagyeong Lee,In-Hye Ham,Hoon Hur,Eunjung Kim,Jae-Young Kim

DOI: https://doi.org/10.1186/s12964-023-01396-7

IF: 7.525

2024-01-02

Cell Communication and Signaling

Abstract:Abstract Background Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) that play an important role in cancer progression. Although the mechanism by which CAFs promote tumorigenesis has been well investigated, the underlying mechanism of CAFs activation by neighboring cancer cells remains elusive. In this study, we aim to investigate the signaling pathways involved in CAFs activation by gastric cancer cells (GC) and to provide insights into the therapeutic targeting of CAFs for overcoming GC. Methods Alteration of receptor tyrosine kinase (RTK) activity in CAFs was analyzed using phospho-RTK array. The expression of CAFs effector genes was determined by RT-qPCR or ELISA. The migration and invasion of GC cells co-cultured with CAFs were examined by transwell migration/invasion assay. Results We found that conditioned media (CM) from GC cells could activate multiple receptor tyrosine kinase signaling pathways, including ERK, AKT, and STAT3. Phospho-RTK array analysis showed that CM from GC cells activated PDGFR tyrosine phosphorylation, but only AKT activation was PDGFR-dependent. Furthermore, we found that connective tissue growth factor (CTGF), a member of the CCN family, was the most pronouncedly induced CAFs effector gene by GC cells. Knockdown of CTGF impaired the ability of CAFs to promote GC cell migration and invasion. Although the PDGFR-AKT pathway was pronouncedly activated in CAFs stimulated by GC cells, its pharmacological inhibition affected neither CTGF induction nor CAFs-induced GC cell migration. Unexpectedly, the knockdown of SRC and SRC-family kinase inhibitors, dasatinib and saracatinib, significantly impaired CTGF induction in activated CAFs and the migration of GC cells co-cultured with CAFs. SRC inhibitors restored the reduced expression of epithelial markers, E-cadherin and Zonula Occludens-1 (ZO-1), in GC cells co-cultured with CAFs, as well as CAFs-induced aggregate formation in a 3D tumor spheroid model. Conclusions This study provides a characterization of the signaling pathways and effector genes involved in CAFs activation, and strategies that could effectively inhibit it in the context of GC.

cell biology

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to investigate the signaling pathways involved in cancer-associated fibroblasts (CAFs) activated by gastric cancer (GC) cells and explore the role of these pathways in the progression of gastric cancer. Specifically:

1. **Identification of Signaling Pathways**: Researchers found that gastric cancer cells activated multiple receptor tyrosine kinase (RTK) signaling pathways through conditioned medium (CM), including ERK, AKT, and STAT3. Notably, tyrosine phosphorylation of PDGFR was activated, but only AKT activation was dependent on PDGFR.

2. **Role of CTGF**: The study found that CTGF (connective tissue growth factor) is one of the most significantly upregulated effector genes in CAFs activated by gastric cancer cells. Knocking down CTGF weakens the ability of CAFs to promote the migration and invasion of gastric cancer cells.

3. **Role of SRC**: The study also found that SRC and its family kinase inhibitors (such as dasatinib and sorafenib) can significantly inhibit the expression of CTGF in activated CAFs and hinder the migration of gastric cancer cells co-cultured with CAFs. Additionally, these inhibitors can restore the expression of epithelial markers (such as E-cadherin and tight junction protein ZO-1) in gastric cancer cells and disrupt the aggregation formation induced by CAFs in 3D tumor spheroid models.

In summary, this paper aims to reveal the specific signaling pathways activated in CAFs in gastric cancer and propose potential therapeutic strategies to inhibit the function of CAFs, thereby overcoming the progression of gastric cancer.